ArticleGynecologic oncology reports2026
Serous borderline tumor progressing to low-grade serous carcinoma after 35 years: a case of extended latency with molecular evidence of clonal relationship.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Low-grade serous ovarian carcinoma (LGSOC) is an uncommon epithelial malignancy that typically arises in the setting of a serous borderline ovarian tumor (SBOT), with the majority of low-grade serous neoplasms harboring mutually exclusive mutations in Case Presentation: Herein, we present the case of a 62-year-old patient with a diagnosis of advanced LGSOC that presented 39 years after her initial diagnosis and 35 years after last documented surgical resection of SBOT. Additionally, we describe the utilization of molecular testing for a Conclusion: This case exemplifies the long-term natural history of low-grade serous neoplasia and highlights how the incorporation of molecular studies can improve diagnostic certainty and guide therapy selection for patients. Further, we provide a review of the literature on SBOT progression to LGSOC, including risk factors for progression and therapeutic options to treat recurrent/progressive disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.